Mitsugumin 29 is transcriptionally induced in senile plaque-associated astrocytes

Kazuki Satoh1, Hiroyasu Akatsu, Takayuki Yamamoto

  • 1Frontier Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo 134-8640, Japan. satoh.kazuki.i6@daiichisankyo.co.jp

Brain Research
|February 1, 2012
PubMed

Insights

Alzheimer's disease (AD) involves astrocytes and beta-amyloid (Aβ). We found mitsugumin 29 (MG29) is upregulated in activated astrocytes in AD brains, potentially altering calcium signaling and accelerating neurodegeneration.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Alzheimer's Disease Research

Background:

  • Astrocytes and beta-amyloid (Aβ) plaques are key in Alzheimer's disease (AD) neuropathology.
  • The precise molecular mechanisms linking Aβ to astrocyte-mediated changes in AD remain unclear.

Purpose of the Study:

  • To identify astrocyte-derived molecules involved in AD exacerbation.
  • To investigate the role of mitsugumin 29 (MG29) in Alzheimer's disease.

Main Methods:

  • Identified a novel Aβ-induced rat gene, MG29, and examined its expression in human AD brains.
  • Analyzed MG29 mRNA in neurons and astrocytes in both AD and non-AD brains.
  • Investigated MG29 protein localization and function in human MG29-transfected cells.

Main Results:

  • MG29 mRNA was found in neurons in non-AD brains but in activated astrocytes near senile plaques in AD brains.
  • MG29 protein localizes to the endoplasmic reticulum and influences Ca²⁺-dependent exocytosis.
  • Increased MG29 expression in AD astrocytes suggests altered intracellular Ca²⁺ homeostasis.

Conclusions:

  • Upregulation of MG29 in activated astrocytes in AD brains may disrupt Ca²⁺ signaling.
  • This disruption could lead to sustained glutamate exocytosis, accelerating neurodegeneration in AD lesions.

Related Concept Videos